Cell line · CVCL_0627
Papers49
1 to 20 of 49
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Model-dependent GD2 upregulation in Ewing sarcoma with the EZH2 inhibitor tazemetostat: Prerequisites for combination with GD2-specific CAR T cells. | Res Sq | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Autophagy impairs the sensitivity of Ewing sarcoma cells to PARP inhibitors. | Cancer Chemother Pharmacol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Unfolded Protein Response as a Therapeutic Target: 4-(Heptyloxy)phenol Induces Programmed Cell Death in Ewing Sarcoma. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Polyamine Depletion by D,L-α-Difluoromethylornithine Inhibits Ewing Sarcoma Metastasis by Inducing Ferroptosis. | Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| PubMed 40376089 | bioRxiv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Identification of novel small molecule inhibitors of ETS transcription factors. | FEBS Lett | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Combined inhibition of ribonucleotide reductase and WEE1 induces synergistic anticancer activity in Ewing's sarcoma cells. | BMC Cancer | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Tumor-derived G-CSF induces an immunosuppressive microenvironment in an osteosarcoma model, reducing response to CAR.GD2 T-cells. | J Hematol Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Engagement of CD99 Activates Distinct Programs in Ewing Sarcoma and Macrophages. | Cancer Immunol Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Inducing Mitotic Catastrophe as a Therapeutic Approach to Improve Outcomes in Ewing Sarcoma. | Cancers (Basel) | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Extracellular vesicle-associated IGF2BP3 tunes Ewing sarcoma cell migration and affects PI3K/Akt pathway in neighboring cells. | Cancer Gene Ther | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Synergistic anticancer activity of combined ATR and ribonucleotide reductase inhibition in Ewing's sarcoma cells. | J Cancer Res Clin Oncol | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Systematic multi-omics cell line profiling uncovers principles of Ewing sarcoma fusion oncogene-mediated gene regulation. | Cell Rep | 2022 | Cellosaurus cites it, and its Methods give the RRID and name the line | PubMed | |
| Relevance of Abnormal KCNN1 Expression and Osmotic Hypersensitivity in Ewing Sarcoma. | Cancers (Basel) | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy. | J Immunother Cancer | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Systematic multi-omics profiling of Ewing sarcoma cell lines. | 2021 | Cellosaurus cites it | DOI | ||
| Quantitative Proteomics of the Cancer Cell Line Encyclopedia. | Cell | 2020 | Cellosaurus cites it | PubMed | |
| Next-generation characterization of the Cancer Cell Line Encyclopedia. | Nature | 2019 | Cellosaurus cites it | PubMed | |
| An Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines. | Cancer Res | 2019 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0627/papers